Pain is a common and heterogeneous complication of multiple sclerosis (MS). In this multicenter, cross sectional study, we aimed at investigating the prevalence of pain in MS using highly specific criteria for distinguishing the different types of pain.
Materials and methods
After a structured interview, in patients with pain, clinical examination and DN4 questionnaire were used for distinguishing neuropathic and nociceptive pain. In subjects with neuropathic pain, the Neuropathic Pain Symptom Inventory was used for differentiating neuropathic pain symptoms.
We enrolled 1249 participants (832 F, 417 M, mean age 33.9 years, mean disease duration 8 years, mean EDSS 3.2); based on clinical evaluation and DN4 score 429 patients (34.34%) were classified with pain (470 pain syndromes): 286 nociceptive pain syndromes and 184 neuropathic pain syndromes. Multivariate analysis showed that pain was associated with age, gender and disease severity and that neuropathic pain was distinctly associated with EDSS.
Our study, providing definite information on the prevalence, characteristics and variables associated with neuropathic pain due to MS, shows that a more severe disease course is associated with a higher risk of neuropathic pain. Our findings might, therefore, provide a basis for improving the clinical management of this common MS complication.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Compston A, Coles A (2008) Multiple sclerosis. Lancet 25(372):1502–1517
Solaro C, Brichetto G, Amato MP et al (2004) The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 63(5):919–921
O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH (2008) Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137:96–111
Truini A, Galeotti F, La Cesa S et al (2012) Mechanisms of pain in multiple sclerosis: a combined clinical and neurophysiological study. Pain 153(10):2048–2054
Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S et al (2013) Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis. Pain. 154(5):632–642
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630–1635
Finnerup NB, Haroutounian S, Kamerman P et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain. 157(8):1599–1606
Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L et al (2010) EFNS guidelines on neurophatic pain assessment: revised 2009. Eur J Neurol 17:1010–1018
Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E et al (2004) Development and validation of the Neurophatic Pain Symptom Inventorry. Pain 108:248–257
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C (2008) prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136:380–387
Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P (2013) Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain 154:2691–2699
Polman CH, Reingold SC, Banwell B et al (2010) Diagnostic oriteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011(69):292–302
Svendsen KB, Jensen TS, Overvad K et al (2003) Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 60(8):1089–1094
Osterberg A, Boivie J, Thuomas KA (2005) Central pain in multiple sclerosis—prevalence and clinical characteristics. Eur J Pain 9(5):531–542
Svendsen KB, Sorensen L, Jensen TS, Hansen HJ, Bach FW (2011) MRI of the central nervous system in MS patients with or without pain. Eur J Pain 15(4):395–401
Hadjimichael O, Kerns RD, Rizzo MA et al (2007) Persistent pain and uncomfortable sensation in persons with multiple sclerosis. Pain 127(12):35–41
Tsang A, Von Korff M, Lee S et al (2008) Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression anxiety disorders. J Pain 9(10):883–891
Truini A, Barbanti P, Pozzilli C et al (2013) A mechanism-based classification of pain in multiple sclerosis. J Neurol 260(2):351–367
Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C (2003) Symptomatic medication use in multiple sclerosis. Mult Scler 9(5):458–460
Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G (2017) Trigeminal neuralgia—diagnosis and treatment. Cephalalgia Int J Headache 37(7):648–657
Solaro C, Allemani C, Messmer Uccelli M, Canevari E, Dagnino N, Pizio R, Regesta G, Tanganelli P, Battaglia MA, Mancardi GL (2005) The prevalence of multiple sclerosis in the north-west Italian province of Genoa. J Neurol 252(4):436–440 (Epub 2005 Feb 23; PubMed PMID: 15726261)
The study was partly supported by an investigator-initiated research grant from Pfizer.
Conflicts of interest
Dr. Solaro served on advisory boards of the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva, Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla). Dr. Signori reported no disclosures. Dr. Martinelli reported no disclosures. Dr. Radaelli reported no disclosures. Dr. Centonze acted as an Advisory Board member of, and received funding for travelling and honoraria for speaking or consultation fees from Merck-Serono, Teva, Genzyme, Bayer Schering, Biogen Idec, Novartis, Almirall, GW Pharmaceuticals. He is the principal investigator in clinical trials for Novartis, Merck Serono, Teva, Bayer Schering, Sanofi-aventis, Biogen Idec, Roche. Dr. Grasso received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla). Dr. Clemenzi reported no disclosures. Dr. Bonavita received honoraria for advisory board and speaking activities from Biogen-Idec, Merck Serono, Teva and Novartis. Dr. D’Ambrosio reported no disclosures. Dr. Patti: received honoraria for advisory board and speaking activities from Almirall, Bayer, Biogen, Merck Serono, Novartis, Sanofi Genzyme and TEVA; he also received research grants from FISM and MIUR. Dr. D’Amico: reported no disclosures. Dr. Cruccu received honoraria for advisory board and speaking activities from Angelini, Biogen, Convergence, Mundipharma e Sigma Tau. Dr. Truini: received research funding, lecture honoraria and acted as speaker or consultant for Mundipharma, Pfizer, Grünenthal, Angelini Pharma, Sigma Tau.
About this article
Cite this article
Solaro, C., Cella, M., Signori, A. et al. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. J Neurol 265, 828–835 (2018). https://doi.org/10.1007/s00415-018-8758-2